GlobeNewswire Inc.··NaHumacyte Posts $2M Revenue as Biotech Pushes Toward FDA Approval Milestone
Biotech firm Humacyte reported $2M in 2025 revenues from 61 Symvess unit sales, secured Saudi Arabia commitment, and targets critical Phase 3 results in Q2 2026.
HUMAHUMAWPhase 3 clinical trialFDA approval